Appendix 4C

Melbourne, Australia, and Leatherhead, UK, 31 July 2017

CLINUVEL PHARMACEUTICALS LTD **(ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY),** a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe and therapeutically unmet genetic disorders announced today its Appendix 4C – Quarterly Cashflow report for the period ended 30 June 2017.

The cash balance as at 30 June 2017 was $23,752,000, an increase of $4,981,000 from the end of the previous quarter.

Cash receipts for the quarter were $6,247,000 compared to $1,597,000 for the previous quarter. The increase in receipts reflects the expanding rollout of the commercial distribution of SCENESSE®. Payments were received from accredited expert centres reflecting the seasonal fluctuations for the demand of SCENESSE® leading into warmer months in the northern hemisphere when patients are at a heightened risk of phototoxic reactions. In addition, during the quarter a R&D tax incentive refund was received from the Australian Taxation Office of $588,000 for the 2015/16 financial year.

Net payments (net of GST refunds) for the quarter were $2,248,000 compared to $2,040,000 for the previous quarter. The combination of cash receipts including the Australian R&D tax incentive and expenditures contributed to a net operating cash inflow result of $4,626,000 for the quarter ended 30 June 2017.

Overall, for the 12 months to 30 June 2017 the Company reports an increase in cash balances of $9,907,000, from $13,845,000 at July 1 2016 to $23,752,000. The increase in cash is primarily generated from its operations, reflecting the Company's initial success in generating revenues from launching a novel, orphan drug in a new market and whilst also containing its overall cost base.

- End -

About SCENESSE® (afamelanotide 16mg)
SCENESSE® (afamelanotide 16mg) is approved in Europe as an orphan medicinal product for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with EPP. The innovative nature of the therapy in an orphan disorder, the lack of available scientific instruments to adequately measure the therapy, ethical considerations and the drug's positive safety profile were some of the factors which led to the European marketing authorisation of SCENESSE®. Information on the product can be found on CLINUVEL's website at www.clinuvel.com

About CLINUVEL PHARMACEUTICALS LIMITED
CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders. As pioneers in understanding the interaction of light and human biology, CLINUVEL's research and development has led to innovative treatments for patient populations with a clinical need for photoprotection and repigmentation. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL's lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care.

Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Switzerland, the US and Singapore. For more information go to http://www.clinuvel.com.

SCENESSE® is a registered trademark of CLINUVEL PHARMACEUTICALS LTD.

Media enquiries
Lachlan Hay, CLINUVEL (UK) LTD. +44 1372 860 765 Lachlan.Hay@clinuvel.com

Investor enquiries
InvestorRelations@clinuvel.com

Forward-Looking Statements

This release to the Australian Securities Exchange and to press may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause CLINUVEL's actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that the FDA may require additional studies beyond the studies planned for product candidates or may not provide regulatory clearances, including for SCENESSE®; that the FDA may not provide regulatory approval for any use of SCENESSE® or that the approval may be limited; that CLINUVEL may never file an NDA for SCENESSE® regulatory approval in the US; that the Company may not be able to access adequate capital to advance its vitiligo programs; that the Company may not be able to retain its current pharmaceutical and biotechnology key personnel and knowhow for further development of its product candidates or may not reach favourable agreements with potential pricing and reimbursement agencies in Europe and the US.

Level 6, 15 Queen Street T +61 3 9660 4900 www.clinuvel.com
Melbourne, Victoria 3000 F +61 3 9660 4999
Australia

+Rule 4.7B

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

CLINUVEL PHARMACEUTICALS LIMITED

ABN	**Quarter ended ("current quarter")**
88 089 644 119	30 JUNE 2017

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	6,247	17,924
1.2	Payments for		
	(a) research and development	(78)	(313)
	(b) product manufacturing and operating costs	(627)	(1,571)
	(c) advertising and marketing	(56)	(185)
	(d) leased assets	(91)	(402)
	(e) staff costs	(1,069)	(4,456)
	(f) administration and corporate costs	(323)	(2,083)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	39	233
1.5	Interest and other costs of finance paid	(4)	(11)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	588	588
1.8	Other/GST & VAT	-	193
1.9	**Net cash from / (used in) operating activities**	**4,626**	**9,917**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire:		
	(a) property, plant and equipment	(21)	(67)
	(b) businesses (see item 10)	-	-
	(c) investments	-	-

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(21)**	**(67)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of shares	-	-
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	85
3.10	**Net cash from / (used in) financing activities**	**-**	**85**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of quarter/year to date	18,772	13,845
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(4,626)	9,917
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(21)	(67)

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	85
4.5	Effect of movement in exchange rates on cash held	(375)	(28)
4.6	**Cash and cash equivalents at end of quarter**	**23,752**	**23,752**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	14,339	9,948
5.2	Call deposits	9,350	8,750
5.3	Bank overdrafts	-	-
5.4	Other (Security Deposits)	63	74
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**23,752**	**18,772**

6.	**Payments to directors of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to these parties included in item 1.2	279
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-

6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Directors' fees

7.	**Payments to related entities of the entity and their associates**	**Current quarter $A'000**
7.1	Aggregate amount of payments to these parties included in item 1.2	-
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-

7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

8.	**Financing facilities available** *Add notes as necessary for an understanding of the position*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
8.1	Loan facilities	-	-
8.2	Credit standby arrangements	-	-
8.3	Other (please specify)	-	-

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

9.	**Estimated cash outflows for next quarter**	**$A'000**
9.1	Research and development	(150)
9.2	Product manufacturing and operating costs	(700)
9.3	Advertising and marketing	(60)
9.4	Leased assets	(90)
9.5	Staff costs	(1,700)
9.6	Administration and corporate costs	(525)
9.7	Other/GST & VAT	50
9.8	**Total estimated cash outflows**	**(3,175)**

10.	Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1	Name of entity	-	-
10.2	Place of incorporation or registration	-	-
10.3	Consideration for acquisition or disposal	-	-
10.4	Total net assets	-	-
10.5	Nature of business	-	-

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Sign here: ..... Date: 31 July 2017

(~~Director~~/Company secretary)

Print name: DARREN KEAMY

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.